...
机译:P3.02B-029主要双重EGFR突变T790M和外显子19或21次突变 - 斯洛伐克NSCLC患者的患病率和治疗结果
Specialised Hospital of St Zoerardus Zobor;
Comenius University Jessenius Medical Faculty and Martin'S Biopsy Centre;
National Cancer Institute;
Comenius University Hospital;
St Elizabeth Cancer Institute;
Specialised Hospital of St Zoerardus Zobor;
Comenius University Jessenius Medical Faculty and Martin'S Biopsy Centre;
National Cancer Institute;
Histopathology Bratislava;
St Elizabeth Cancer Institute;
Outpatient Oncology Department;
National Cancer Institute;
Dalion Oncology Outpatient Department;
Alpha Medical Laboratory of Molecular Genetics;
机译:P3.02B-029主要双重EGFR突变T790M和外显子19或21次突变 - 斯洛伐克NSCLC患者的患病率和治疗结果
机译:含有双EGFR突变的三种EGFR TKI幼稚肺腺癌的病例报告(L858R / T790M或EXON 19删除/ T790M); 比较遗传信息和组织学
机译:P3.02B-002在高级NSCLC患者中二线TKI后的外显子19和21 EGFR突变的治疗结果比较
机译:单细胞水平晚期NSCLC患者EGFR激活突变的细胞内异质性
机译:用于EGFR基因外显子18-21突变检测的LATE-PCR和开/关灯探针检测的设计,构建和验证:对非小细胞肺癌的分子诊断意义
机译:非小细胞肺癌一线EGFR-TKI治疗后EGFR外显子19或21外显子突变与生存率的关系
机译:CN2用于一线治疗转移性非小细胞肺癌(Nsclc)Egfr外显子19缺失或外显子21(L858r)取代突变的患者的比较成本效用分析